Summary A phase trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a multi-institutional phase 11 study. Seventy patients with stage IIIB or IV NSCLC received CPT-11 60 mg m-2 intravenously (IV) on days 1, 8 and 15, and cisplatin 80 mg m-2 (IV) on day 1 every 4 weeks. Assessments were made of response, survival and toxicities. Sixty-nine were eligible, and evaluable for toxicities and survival, and 64 patients evaluable for response. Thirty-three patients (52%; 95% confidence interval 39-64%) achieved an objective response, with one complete response (2%) and 32 partial responses (50%). The median duration of response was 19 weeks and the overall median survival time was 44 weeks. The 1-year survival rate was 33%. The major toxic effects were leucopenia and diarrhoea. Grade 3 or 4 leucopenia, neutropenia, and diarrhoea occurred in 32 patients (46%), 53 patients (80%), and 13 patients (19%) respectively. A combination of CPT-11 and cisplatin is very effective against non-small-cell lung cancer with acceptable toxicities.
Lung cancer is a major health care problem throughout the world. Non-small-cell lung cancer (NSCLC) accounts for approximately 75% of all lung cancers. Only a small proportion of patients will be cured by surgery, and most will have metastatic disease and require systemic treatment. Unfortunately, NSCLC is in the group of neoplastic diseases that are relatively chemoresistant. Although a modest survival benefit was noted by meta-analysis (Grilli et al, 1993; Souquet et al, 1993) , no regimen is completely effective and none has led conclusively to a cure, and there is no standard chemotherapy programme for this disease (Ginsberg et al, 1993) . Therefore, it is imperative to develop combination regimens of new active compounds with novel mechanisms of actions.
Irinotecan (CPT-11) is a water-soluble camptothecin derivative that targets DNA topoisomerase I. CPT-11 has shown a strong anti-tumour activity as a single agent against a broad spectrum of experimental tumours (Kunimoto et al, 1987; Matsuzaki et al, 1988) as well as against various human malignancies including lung cancer (Ohno et al, 1990; Negoro et al, 1991b; Tacheuchi et al, 1991; Fukuoka et al, 1992 ; Masuda et al, 1992a; Shimada et al, 1993) .
The response rate of 32% to CPT-11 for NSCLC is very encouraging (Fukuoka et al, 1992) . Both CPT-11 and cisplatin are active against NSCLC. Because of the differences in mechanisms of action (Andoh et al, 1987; Zwelling and Kohn, 1979) and toxicity profiles (Gottlieb and Drewinko, 1975; Negoro et al, 1991a) , and with limited cross-resistance Noda et al, 1991; Masuda et al, 1992a) between the two drugs, the synergism between CPT-11 and its major active metabolite, in combination with cisplatin seems to have enormous clinical potential. Based on these reports, we conducted a phase I trial of the combination of CPT-11 (escalating doses) with cisplatin in advanced NSCLC (Masuda et al, 1992b) . A response rate of 54% in previously untreated NSCLC patients was very encouraging, even although some patients received relatively low doses of CPT-11. The results of the pilot study led to the multi-institutional phase II study reported here, which was designed to determine the antitumour activity and toxicities of a combination of CPT-11 and cisplatin in previously untreated patients with advanced NSCLC.
PATIENTS AND METHODS Patient selection
Before participation in the study, each patient was examined to make sure he or she met the following criteria: (a) histological diagnosis of non-small-cell lung cancer; (b) stage IIIB or IV disease; (c) no prior chemotherapy or radiotherapy; (d) life expectancy of at least 8 weeks; (e) age < 75 years; (f) performance status of 2 or better on the Eastern Cooperative Oncology Group (ECOG) scale; (g) adequate bone marrow function (leucocyte count . 4000 l1-', platelet count 2 100 000,l-and haemoglobin concentration 2 9 g dl-'), hepatic function (bilirubin < 1.5 mg dl-, transaminases < 2 x upper limit of normal), and renal function (creatinine < upper limit of normal, creatinine clearance 2 60 ml min-1); (h) free of any concurrent active malignancy; (i) no medical problems sufficiently severe to prevent compliance with the study requirements; and (j) written informed consent of the 
Treatment plan
CPT-11 at a dose of 60 mg m-2 was given in 500 ml of normal saline as a 90 min intravenous infusion on days 1, 8 and 15 every 4 weeks. CPT-11 was provided by Daiichi Pharmaceutical, Tokyo, Japan, and Yakult Honsha, Tokyo, Japan. A 80 mg m-2 sample of cisplatin was given on day 1 after the CPT-11 administration every 4 weeks. These doses were the recommended doses of a combination of CPT-11 and cisplatin in a previous phase I/II study (Masuda et al, 1992b) . During the course of the treatment, the dose of CPT-1I was withheld in instances of leucocyte count <3000 ,ul-, platelet count <100 000,l-1 or grade >2 diarrhoea on the day when the dose was due. Patients with obvious evidence of disease progression or unmanageable toxicity were removed from the study. Patients who were stabilized received at least a second course of treatment; those with objective tumour response were eligible to continue therapy for a maximum of six courses. Before the next course was started, the WBC count had to be 4000 ul-' or higher, the platelet count had to be 100 000 pl-I or higher, the serum creatinine level had to be normal and diarrhoea should be recovered completely. Subsequent doses were modified on the basis of haematological and non-haematological toxicities. If during the previous cycle the leucocyte nadir was <2000 ,ul-' and/or the platelet nadir was <50 000 ,l' or if the subsequent cycle was delayed for more than 2 weeks, the dose of CPT-11 was reduced to 50 mg m-2. The dose of CPT-11 was also reduced to 50 mg m-2 in cases of diarrhoea > grade 3. A prophylactic anti-diarrhoeal regimen was not used in this trial. If the serum creatinine concentration was > 1.7 mg dl-', or the creatinine clearance was below 60 ml min-', the cisplatin dose was reduced to 60 mg m-2. Dose adjustments were also made for other toxicities 2 grade 3, except for nausea and vomiting, and alopecia.
Evaluation
Patients were evaluated to determine the stage of disease by complete medical history and physical examination, routine chest radiograph, whole-lung tomography, bone scintiscan, computerized tomography of the head, chest and abdomen, and fibreoptic bronchoscopy. The staging procedures were those of the tumour-node-metastasis system (Mountain, 1986) . Before the first course, each patient was subject to a complete blood count (CBC), including a differential count and a platelet count, and serum chemistry was used to check renal and hepatic functions, electrolytes and urinalysis. CBC, serum chemistry, electrolytes, urinalysis, and chest radiographs were assessed at least once a week after the initial evaluation. Other appropriate investigations were repeated weekly to evaluate the sites of marker lesions. After the completion of chemotherapy, each patient was restaged with all the tests used during the initial work-up, except for the fibreoptic bronchoscopy. The eligibility, evaluability and response of each patient were assessed by extramural reviewers. The tumour responses and toxicities, except diarrhoea, were classified in accordance with the World Health Organization (WHO) criteria 
Statistical methods
The method of Kaplan and Meier (1958) 
Toxicity
There were two treatment-related deaths on days 8 and 15 of cycle I as a result of neutropenic sepsis coincidentally associated with paralytic ileus. Another nine patients were taken off the study after the first cycle of treatment because of progressive disease (two), patient refusal (one), severe diarrhoea (two), paralytic ileus (one), delayed recovery from leucopenia (one), pulmonary toxicity (one) and skin rash (one). Fifty-eight patients received multiple courses of treatment in successive cycles. A total of 175 courses were given; all were valid for toxicity analysis (mean cycles per patient, 2.5: range 1-6). Reduction of the cisplatin dose was required in only two patients (three cycles). Details of the CPT-11 dose actually delivered are listed in Table 3 . Thirty-six (52%) of 69 patients could receive CPT-11 treatment three times during cycle 1. Virtually all episodes of severe leucopenia and/or diarrhoea were observed during cycle I as dose modifications were made in subsequent cycles. Consequently, it was possible to deliver the full doses of CPT-II treatment (three times) in 59% of the entire 175 cycles, suggesting little evidence of cumulative toxicity during the subsequent courses of treatment. The reasons why patients could not receive CPT-1 I treatment three times in the first course were treatment-induced leucopenia (33%), thrombocytopenia (9%) and/or diarrhoea ( 17%). neutropenia (absolute neutrophil count <500 tl). Among 69 patients, 29 (42%) patients received granulocyte colony-stimulating factor when they experienced leucopenia. Transient eosinophilia in 10% or more of leucocytes was observed in 12 (18%) of 67 patients. Thrombocytopenia remained infrequent throughout the study: grade 3 and 4 toxicity only occurred in 3% and 6% of the patients respectively. Thirty-five per cent of patients had grade 3 or 4 anaemia. Non-haematological toxicities were also significant. Gastrointestinal toxicity was a prominent toxic effect of this treatment.
Grade 3 nausea and vomiting occurred in 24 (35%) patients. Grade 3 and 4 diarrhoea was observed in 10 (14%) and 3 (4%) patients. Maximal grade diarrhoea occurred on a median of day 11 (range: day 1-18), and recovery was observed in a median of 4 days (range: 1-12 days). Although treatment of diarrhoea was left at the discretion of the treating physicians, most of the patients with diarrhoea were treated with loperamide, as reported by Abigerges et al (1994) . However, three (4%) patients experienced grade 4 paralytic ileus, two of whom died early in the treatment as described above. No severe toxicities were observed in the urinary bladder, kidney or liver. Grade 4 pulmonary toxicity occurred only in one (1 %) patient, who developed severe hypoxaemia during his first course of treatment and required mechanical ventilation.
DISCUSSION
As the majority of patients die from advanced NSCLC, there is a compelling need for more effective treatment that offers a realistic possibility of improving the survival in these patients. The current multi-institutional phase II trial of CPT-11 and cisplatin in combination for advanced NSCLC demonstrates the encouraging response rate of 52%, confirming the preliminary response rate of 54% obtained in a previous phase I trial in advanced NSCLC (Masuda et al, 1992b) . A response rate of 30-40%, a median survival time of 6-9 months, and a 1-year survival of approximately 20% are commonly seen in treatments with cisplatin-based regimens, usually in combination with etoposide or a vinca alkaloid (Cellerino et al, 1990; Splinter, 1991; Bunn, 1992) . Therefore, the response rate obtained in this study is in the upper range of the reported trials in NSCLC among combination chemotherapy regimens currently in use. As the high response rate of 52% and the 1-year survival rate of 33% obtained here are encouraging, this combination holds promise not only as primary therapy for patients with metastatic disease (stage IV) but also for patients with more localized disease in the adjuvant or neoadjuvant (induction) setting in combination with surgery and/or radiotherapy. In the last two instances a better efficacy of this combination regimen is expected because improved response rates to chemotherapy in patients with a lower tumour burden have been demonstrated in patients with NSCLC (Donnadieu et al, 1991 ) and other solid tumours (Hong and Bromer, 1983) . Recently, a number of other new chemotherapeutic agents with substantial activity against NSCLC, including vinorelbine, paclitaxel, docetaxel and gemicitabine, have become available (Lilenbaum and Green, 1993) . The inclusion of these agents in combination chemotherapy regimens may provide a substantial improvement in the treatment of this disease. Pirker et al (1995) (1998) 78(2), [251] [252] [253] [254] [255] [256] carboplatin in 53 patients with advanced NSCLC. In contrast, Johnson et al (1996) used the same paclitaxel and carboplatin combination and obtained a relatively disappointing response rate of 27%, a median survival time of 38 weeks, and a 1-year survival of 32% in patients with stage IV NSCLC. Prospective randomized trials that compare these new combination regimens with an existing cisplatin-containing regimen are necessary to determine whether or not these new agents will truly improve therapeutic options for patients with advanced NSCLC.
One of the major arguments against the use of chemotherapy for NSCLC concerns the considerable toxicity. As expected, leucopenia and diarrhoea, which are typical toxicities of CPT-1 I (Fukuoka et al, 1992) , were the major toxicities of this combination regimen, with the most severe toxicities occurring during cycle I (Table 3 ). The marked interpatient variation in the toxicities, which is a well-known feature of CPT-11 (Masuda et al, 1992b; , was also noted in this trial. Two patients died on days 8 and 15 after experiencing severe leucopenia simultaneously with severe diarrhoea. These lethal toxicities occurred very rapidly with unpredictable severity during cycle 1. Patients who could tolerate cycle 1 without major toxic effects were less likely to experience severe toxicities in subsequent cycles without dose adjustments. Despite the dose modification procedure, in which CPT-I I was withheld if the leucocyte count was < 3000 il-I when treatment was due, grade 3 or 4 leucopenia more frequently occurred in this trial than in a previous phase II trial of CPT-11 given as a single agent (46% vs 25%) (Fukuoka et al, 1992) , suggesting at least an additive leucopenic effect in combination with cisplatin. With the availability of recombinant human granulocyte colony-stimulating factor (rhG-CSF), it has become possible to reduce the severity and duration of leucopenia induced by cytotoxic chemotherapy (Gabrilove et al, 1988) . At the time of the current trial rhG-CSF had already become commercially available. However, the frequency of severe leucopenia did not decrease in the current study. This may be in part explained by the fact that the use of rhG-CSF is allowed in Japan only in patients who experience leucopenia of grade 3 or worse. Diarrhoea was another principal dose-limiting toxicity observed with this combination regimen (Table 4 ). The recent introduction of the use of high-dose loperamide by Abigerges et al (1994) has substantially reduced the previously marked CPT-11 -induced diarrhoea. However, 19% of patients still suffered from grade 3 or 4 delayed diarrhoea in this trial. Diarrhoea of grade 3 or 4 occurring coincidentally with grade 4 leucopenia and high fever was especially life-threatening or lethal, in spite of active supportive care including vigorous intravenous hydration and intravenous administration of broad-spectrum antibiotics. Much improvement in the control of this toxic effect is required to make it more easily to apply safely to a wide variety of patients. Therefore, further studies to pursue effective methods of overcoming this late diarrhoea are necessary.
In conclusion, the combination of CPT-11 and cisplatin is an effective regimen in advanced NSCLC, with a response rate and survival time that favourably compare with the results of many other combination chemotherapy regimens in advanced NSCLC.
As the combination of cisplatin and vindesine is the regimen that has been reported to prolong survival by 10 weeks when compared with the best supportive care (Grilli et al, 1993; Souquet et al, 1993; Non-small Cell Lung Cancer Collaborative Group, 1995) , it seems useful to compare the effect of these two combination chemotherapy regimens. Its final role in the treatment of this disease will be made clear by a currently on-going prospective randomized trial comparing CPT-11 alone vs a combination of CPT-11 and cisplatin vs a combination of cisplatin and vindesine in treating patients with advanced disease. Another trial comparing a combination of CPT-1I and cisplatin vs a combination of cisplatin and vindesine in advanced non-small cell lung cancer is also in progress in Japan.
